For research use only. Not for therapeutic Use.
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research[1][2].
Denifanstat (compound 152) is a potent FASN inhibitor[2]. ?
Fatty Acid Synthase (FASN) inhibition prevents palmitoylation of SARS-CoV2 spike protein[1].
| Catalog Number | I018755 |
| CAS Number | 1399177-37-7 |
| Synonyms | 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile |
| Molecular Formula | C27H29N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C27H29N5O/c1-17-14-24(22-4-3-5-22)25(26-29-18(2)30-31-26)15-23(17)27(33)32-12-10-21(11-13-32)20-8-6-19(16-28)7-9-20/h6-9,14-15,21-22H,3-5,10-13H2,1-2H3,(H,29,30,31) |
| InChIKey | BBGOSBDSLYHMRA-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C=C1C(=O)N2CCC(CC2)C3=CC=C(C=C3)C#N)C4=NNC(=N4)C)C5CCC5 |
| Reference | [1]. Minhyoung Lee, et al. Fatty Acid Synthase inhibition prevents palmitoylation of SARS-CoV2 Spike Protein and improves survival of mice infected with murine hepatitis virus. BioRxiv, December 21, 2020. [2]. Johan D., et al. Heterocyclic modulators of lipid synthesis. WO2012122391A1. |
